Citius Oncology (CTOR) Q4 2024 earnings summary

Executive summary

• Achieved FDA approval for LYMPHIR (denileukin diftitox-cxdl) for relapsed or refractory cutaneous T-cell lymphoma (CTCL) in adults.

• Completed merger and began trading on Nasdaq as a standalone oncology company under ticker CTOR in August 2024.

• Advanced commercial launch preparations for LYMPHIR, including manufacturing, supply chain, and field force recruitment.

• Supported investigator-initiated trials for LYMPHIR as a combination immunotherapy, with promising interim results in solid tumors.

Financial highlights

• R&D expenses rose to $4.9 million for FY 2024 from $4.2 million in FY 2023, reflecting increased development activity.

• G&A expenses increased to $8.1 million from $5.9 million year-over-year, driven by pre-commercial and launch activities.

• Stock-based compensation expense surged to $7.5 million from $2.0 million year-over-year due to full-year realization.

• Net loss widened to $21.1 million, or ($0.31) per share, compared to $12.7 million, or ($0.19) per share, in FY 2023.

Outlook and guidance

• Commercial launch of LYMPHIR planned for the first half of 2025, with ongoing marketing and patient support initiatives.

• Preliminary results from a second investigator trial with CAR-T therapies expected in 2025.

• Management anticipates greater access to capital post-merger to fund growth and product launch.